Science · 2020 · 122 citations · 43 references
Life SciencesInfectious DiseasesMolecular BiologyImmunology Of Infectious DiseasesMolecular VirologyVirologyAntiviral ImmunityAntiviral ResistanceAntiviral TherapyMajor Histocompatibility ComplexViral InfectionsViral PathogenesisHost Cell Restriction FactorsMhc Class Ii MoleculesMhc Class Ii TransactivatorResistance To Viral InfectionSars-cov-2 Antiviral ResistanceSars-cov-2 Antiviral TherapySars-cov-2 InfectionViral Restriction Factors
Recent outbreaks of Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have exposed our limited therapeutic options for such diseases and our poor understanding of the cellular mechanisms that block viral infections. Using a transposon-mediated gene-activation screen in human cells, we identify that the major histocompatibility complex (MHC) class II transactivator (CIITA) has antiviral activity against EBOV. CIITA induces resistance by activating expression of the p41 isoform of invariant chain CD74, which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein. We further show that CD74 p41 can block the endosomal entry pathway of coronaviruses, including SARS-CoV-2. These data therefore implicate CIITA and CD74 in host defense against a range of viruses, and they identify an additional function of these proteins beyond their canonical roles in antigen presentation.
43
Enzymatic assembly of DNA molecules up to several hundred kilobases
Daniel G. Gibson, Lei Young, Ray-Yuan Chuang et al. · Nature Methods · 2009 · 10.9K citations
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali, Luhan Yang, Kevin M. Esvelt et al. · Science · 2013 · 9.4K citations · Full text
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15